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ABSTRACT
Immune-mediated bone loss significantly impacts fracture risk in patients with autoimmune disease, but to what extent individual
variations in immune responses affect fracture risk on a population level is unknown. To examine how immune responses relate
to risk of hip fracture, we looked at the individual variation in a post-vaccination skin test response that involves some of the immune
pathways that also drive bone loss. From 1963 to 1975, the vast majority of the Norwegian adult population was examined as part of
the compulsory nationwide Norwegian mass tuberculosis screening. These examinations included standardized tuberculin skin tests
(TSTs). Our study population included young individuals (born 1940 to 1960 and aged 14 to 30 years at examination) who had all
received Bacille Calmette-Guerin (BCG) vaccination after a negative TST at least 1 year prior and had no signs of tuberculosis upon
clinical examination. The study population ultimately included 244,607 individuals, whose data were linked with a national database
of all hospitalized hip fractures in Norway from 1994 to 2013. There were 3517 incident hip fractures during follow-up. Using a pre-
defined Cox model, we found that men with a positive or a strong positive TST result had a 20% (hazard ratio [HR] = 1.20, 95% con-
fidence interval [CI] 1.01–1.44) and 24% (HR = 1.24, 95% CI 1.03–1.49) increased risk of hip fracture, respectively, compared with men
with a negative TST. This association was strengthened in sensitivity analyses. Total hip bone mineral density (BMD) was available
for a limited subsample and similarly revealed a non-significantly reduced BMD among men with a positive TST. Interestingly, no
such clear association was observed in women. An increased immune response after vaccination is associated with an increased
risk of hip fracture decades later among men, possibly because of increased immune-mediated bone loss. © 2020 The Authors.
Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral
Research (ASBMR).
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Introduction
The term osteoimmunology was coined in 2000
(1) and has
become a shorthand for the interplay between bone and
immune system. A large part of this interplay is facilitated by
cytokines released from activated T cells, which affect bone
remodeling in different ways. Most activated T cells release cyto-
kines that inhibit rather than stimulate bone loss.(2,3) T-helper cell
17 (Th17) is an exception to this because the exhibited cytokines
are mainly stimulatory on osteoclastogenesis.(4) Th17 activity is
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also linked to the development of multiple inflammatory
disorders.(5–8) These Th17-mediated immune responses are
known to impact bone health in inflammatory conditions such
as rheumatoid arthritis,(9) but it is still unclear to what extent they
impact bone health in the general population.
Vaccines have presented an opportune way to investigate
immune system variation(10) because they are a standardized
and well-documented form of exposure. There are, however,
few examples of post-vaccination responses routinely being
measured. The tuberculin skin test (TST) has been employed
since the early 20th century primarily to detect infection with
tuberculosis(11) but also to document the immunological reac-
tion to the Bacille Calmette-Guerin (BCG) vaccine. The test is con-
ducted by intracutaneously applying antigens derived from
tubercle bacilli. This produces a skin induration if the individual
has undergone a prior sensitization toward the injected anti-
gens, commonly from a BCG vaccination or much less common
from environmental mycobacteriae or tuberculosis infection.
Because the test predates many of the discoveries that define
modern immunology, such as the identification of B and T cells,
our understanding of it has changed over time. After the charac-
terization of Th17 during the early 2000s,(12,13) it has been shown
that Th17 activity could be crucial to establish a post-BCG-
vaccination response(14,15) and also that a lack of Th17 activity
severely inhibits the delayed-type hypersensitivity response
measured by TST.(16)
From 1948 to 1975, 80% to 85% of the Norwegian adult pop-
ulation were routinely examined as part of a mandatory mass
tuberculosis screening.(17) These examinations included chest
X-rays, TST, documentation of BCG vaccination status, and
vaccination of previously unvaccinated persons with a negative
TST. Even those who had a previously documented BCG vaccina-
tion, commonly as part of the national school vaccination pro-
gram at age 12 to 14, underwent testing with TST. Since the
incidence of tuberculosis in Norway declined rapidly from the
1930s onward,(18,19) the majority of positive TSTs among those
previously BCG vaccinated reflected prior vaccination rather
than exposure to environmental mycobacteria or infection with
tuberculosis.
Given a prior BCG vaccination and subsequent testing with
TST under standardized conditions, the variation in TST results
among younger individuals should reflect individual variation
in immune responses, rather than environmental exposure to
mycobacteria. We therefore aimed to answer the following
questions:
Is an increased post-vaccination immune response, as quanti-
fied by TST after BCG vaccination in young adulthood, associ-
ated with:
a. an increased risk of hip fracture three to four decades later?
b. lower bone mineral density three to four decades later?
Materials and Methods
Study population
Norwegian mandatory mass tuberculosis screening and BCG
vaccination program
The nationwide Norwegian mandatory mass tuberculosis
screening and BCG vaccination program (from here on referred
to as the screening program) was conducted in the period
1948 to 1975. It aimed to reduce the risk of tuberculosis through
examination of all individuals above school age with chest X-ray
and TST. Unvaccinated persons with a negative TST were offered
BCG vaccination. BCG was produced at the Bergen State BCG
Laboratory (Bergen, Norway) using the Swedish Gothenburg
strain until 1973.(20) From then it was provided by Statens Serum
Institute (Copenhagen, Denmark). Liquid BCG was gradually
replaced by freeze-dried BCG between 1959 and 1973.(21)
Computerized records of these examinations are available
from 1963 to 1975, including 1,911,600 individuals. The screen-
ing program covered all counties in Norway except the capital
Oslo, where inhabitants were screened in a separate program.
Selection of the study population for our study is described in
Fig. 1. We aimed to include young, vaccinated individuals with an
available TST result.
There were 389,772 individuals that matched our predefined
criteria of being born 1940 to 1960 and aged 14 to 30 years at
examination with TST. Only calendar year for vaccination and
TST were available. Therefore, to ensure that vaccination had
preceded TST, the sample was limited to individuals with a previ-
ously documented BCG vaccination at least 1 year before exam-
ination with TST (275,330 individuals; 70.6%).
The national school vaccination program in Norway was grad-
ually implemented from the early 1950s, during 6th to 8th grade
(ages 12 to 14 years) with very high coverage. According to
expectations, 208,743 (75.8%) of the considered individuals
had received a vaccination during ages 12 to 14. Only children
with a previously confirmed positive TST after suspected infec-
tion with tuberculosis were to be exempted from vaccination.
The final study population did also include individuals who had
received vaccination at age >14 years.
Fig 1. Study population.
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We also excluded 21,356 (7.8%) individuals who were vacci-
nated before 12 years of age (ie, before the national school vac-
cination program), since it was likely that most of them had been
in close contact with tuberculosis patients and had a high prob-
ability of being infected with tuberculosis. We also excluded
1185 individuals who for any reason were referred for further
evaluation after examination with chest X-ray. Of the remaining
252,789 individuals, 244,607 were alive and living in Norway on
January 1, 1994.
Exposure
Tuberculin skin test - adrenaline Pirquet
For TST, the adrenaline Pirquet (aP) method was used with Old
Tuberculin, measuring infiltrates according to strict national
guidelines during the screening program, which is described
by Waaler and colleages.(22) All aP/TST measurements used in
the following analysis were conducted between 1954 and 1975
(99% between 1963 and 1975). Two skin scratches of 5 mm
length were applied to the volar side of the distal left arm. After
48 hours (maximum 72 hours), the largest of the two infiltrates
were recorded in mm.
During the Norwegian mandatory mass tuberculosis screen-
ing and BCG vaccination program, the aP test was categorized
as negative (<4 mm) or positive (≥4 mm),(22) although positive
reactions of ≥8 mm were sometimes referred to as strong posi-
tive reactions. A previous study defined a strong positive reac-
tion as ≥10 mm,(23) whereas Bjartveit briefly mentions a strong
reaction as ≥8 mm.(24) In our analyses, we accordingly catego-
rized the aP tests as negative (<4 mm), positive (≥4 mm), or
strong positive (≥8 mm), and performed sensitivity analyses with
infiltrates of ≥10 mm being considered strong positive rather
than ≥8 mm. All mentions of TST in Results refer to aP
measurements.
Outcomes
Hip fracture – NORHip
Data on all cervical, trochanteric, or subtrochanteric hip frac-
tures treated in Norwegian hospitals from January 1, 1994,
through December 31, 2013, were retrieved from the NORHip
database compiled by the Norwegian Epidemiologic Osteopo-
rosis Studies (NOREPOS) research network.(25) We did not have
access to data regarding potential hip fractures before 1994, as
this was the first year all hospitals used electronic patient
administrative systems. Only the first hip fracture for each indi-
vidual was included in the analysis. We could not differentiate
between high- and low-energy hip fractures. Information on
definitions, classification, quality assurance, and validation of
data collection for the NORHip database is available at www.
norepos.no/documentation.
The National Registry provided dates of emigration and death.
Of the 252,789 individuals eligible for inclusion from the screen-
ing program, 244,607 (from here on referred to as the study pop-
ulation) were alive and living in Norway on January 1, 1994, and
were included in the analyses (Fig. 1). Each individual was fol-
lowed from January 1, 1994, to the date of his or her first hip frac-
ture, emigration, death, or end of follow-up December 31, 2013,
whichever occurred first. An overview of the timeline for expo-
sure and outcome is presented in Fig. 2.
Bone mineral density
Bonemineral density (BMD) in the total hip at mean age 52 years
(range 45 to 62 years) was available in a subsample of dual-
energy X-ray absorptiometry (DXA) scans performed in the Hor-
daland Health Study (HUSK) 1997 to 2000 and the fifth Tromsø
Study (Tromsø 5) 2001 to 2002. Both studies used GE Lunar den-
sitometers (GE Lunar, Madison, WI, USA): Tromsø 5 used Prodigy,
while HUSK used EXPERT-XL. Dual hip scans were performed in
Tromsø 5. The left hip was scanned in HUSK, unless there was a
history of previous fracture or surgery, whereupon the right hip
was scanned. The measurements have been cross-calibrated.(26)
We have included left hip scans where available, and right hip
scans if left was missing (n = 25). There were a total of 849 BMD
total hip measurements available for the individuals included in
our study population, 493 from HUSK and 356 from Tromsø 5.
Statistical methods
Data were analyzed using Stata for Windows (version 15.0, Stata
Corporation, College Station, TX, USA). Risk estimates (hazard
ratios) of hip fracture according to TST infiltrate were obtained
using a multivariable Cox proportional hazards model with time
on study scales. TST was both entered as a continuous as well as
a categorical variable during analyses. Categories were deter-
mined based on Cox regression with cubic splines (5 knots)
and hazard estimates from the described Cox model, as well as
the size of each group. The results from the spline analysis were
in accordance with the previously described clinical categoriza-
tion.(23,24) We therefore categorized TST infiltrate size into three
levels: negative (<4 mm, reference), positive (≥4 mm), and
strong positive (≥8 mm). In addition, the predefined Cox models
included the following covariates: age at TST (years), time from
BCG vaccination to TST (years), time from TST to start of follow-
up (years), BMI (categorical, <18.5, <25, <30, ≥30), and county
(categorical). The time from BCG vaccination to TST was included
in the model to standardize the TST measurements, since this
time is known to impact the infiltrate size.(27,28)
In sensitivity analyses, Cox models corresponding to those
described above were performed: (i) limited to individuals born
1945 or later; (ii) limited to those who had received BCG vaccina-
tion at age 12 to 14 years, which is most likely as part of the
school vaccination program; and (iii) defining a strong positive
TST response as >10 mm rather than >8 mm.
Differences in total hip BMD between categories of TST
response were evaluated using a linear regression model that
included the same covariates as the described Cox model,
except for “time from TST to start of follow-up,” which was
substituted for “time from TST to BMD measurement.”
The Student’s t test was used to compare means for indepen-
dent samples with normal distribution, whereas the Mann–
Whitney U test was used for samples with non-normal distribu-
tion. The chi-square test was used to compare frequencies
between groups. Pearson’s r is reported when measuring linear
correlation.
A p value of <0.05 was considered statistically significant.
Where deemed appropriate, 95% confidence intervals (CI) are
reported.
Ethics
The study and the data linkages have been approved by the
Regional Committee for Medical and Health Research Ethics, Sta-
tistics Norway, The Norwegian Directorate of Health, and the
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Norwegian Institute of Public Health. Use of dates of deaths and
emigration from the National Registry was approved by the Nor-
wegian Tax Administration. Data from the Norwegian Patient
Registry have been used in this publication. The interpretation
and reporting of these data are the sole responsibility of the
authors, and no endorsement by the Norwegian Directorate of
Health is intended nor should be inferred.
Results
There were 119,693 men (48.9%) and 124,914 women (51.1%) in
the study population (Table 1). The mean TST infiltrate was
6.2 mm (range 0 to 60, SD 2.8), with men having a mean infiltrate
that was 0.5 mm larger than women (p < 0.001). A total of 40,450
individuals (16.5%) were TST negative (<4 mm). Among the
204,157 TST positive, 122,787 (60.1%) had an infiltrate size of
4 to 7 mm, 52,225 (25.6%) had an infiltrate size of 8 to 9 mm,
and 29,145 (14.2%) had an infiltrate size of ≥10 mm. The mean
time between BCG vaccination and measurement of TST was
6.8 years (SD 4.2 years), and the mean age at the time of
examination with TST was 20.4 years (SD 4.4 years). There was
a significant positive correlation between the size of the TST infil-
trate and the time that elapsed between BCG vaccination and
measurement of TST (Pearson’s r = 0.203, p < 0.001).
Hip fracture
There were 3517 (1.4%) incident first hip fractures in the study
population during follow-up. The mean age at the time of frac-
ture was 59.7 years (SD 6.9 years) among men and 61.4 years
(SD 6.3 years) among women. A total of 59% of the fractures
occurred among women.
Among the men, there were 4.89, 6.13, and 7.09 fractures per
10,000 person-years in the negative (<4 mm), positive (≥4 mm),
and strong positive (≥8 mm) groups, respectively, whereas for
women there were 8.74, 8.22, and 9.22.
These unadjusted trends were also reflected in the multivari-
able Cox proportional hazard model (Table 2). Men with a posi-
tive (≥4 mm) or a strong positive (≥8 mm) TST infiltrate had a
20% (hazard ratio [HR] = 1.20, 95% confidence interval
[CI] 1.01–1.44) and 24% (HR = 1.24, 95% CI 1.03–1.49) increased
risk of hip fracture, respectively, compared with those with a
negative reaction (<4 mm). There was no significant difference
in risk among women with either a positive (HR = 0.89, 95% CI
0.79–1.00) or strong positive reaction (HR = 0.90, 95% CI
0.79–1.02) compared with those with a negative one. Data are
presented in Table 2.
TST as a continuous measure (millimeters) was not signifi-
cantly associated with risk of hip fracture in any of the Cox
models (Table 2).
Sensitivity analyses
Excluding all individuals born before 1945 (birth year range 1940
to 1944) yielded similar but somewhat stronger effect estimates.
Men with a positive or a strong positive TST infiltrate had a 25%
(HR = 1.25, 95% CI 1.01–1.54) and 30% (HR = 1.30, 95% CI
1.04–1.62) increased risk of hip fracture, respectively, compared
with those with a negative reaction. Again, there was no signifi-
cant difference among women (HR = 0.94, 95% CI 0.80–1.09
and HR = 1.01, 95% CI 0.85–1.19, respectively).
Restricting the analysis to those who had received BCG vacci-
nation during ages 12 to 14 (most likely as part of the school vac-
cination program) also yielded similar and somewhat stronger
Fig 2. Timeline for exposure (vaccine and skin test) and outcome (hip fracture). Illustrations modified from Servier Medical Art by Servier (Creative Com-
mons License).







Age at tuberculin skin test (TST),
mean years (SD)
20.3 (4.4) 20.5 (4.4)
Age at BCG vaccination, mean
years (SD)
13.6 (2.1) 13.5 (2.0)
Time between BCG vaccination
and TST, mean years (SD)
6.7 (4.2) 7.0 (4.2)
TST infiltrate size,
mean mm (SD)
6.4 (2.7) 5.9 (2.9)
TST negative individuals, n (%) 15 881 (13.3) 24 569 (19.7)
Body mass index (BMI), mean
(SD)a
22.2 (2.8) 21.9 (3.0)
Hip fracture during follow-up,
n (%)
1 437 (1.2) 2 080 (1.7)
Age at hip fracture,
mean years (IQR)
59.7 (6.9) 61.4 (6.3)
a85 men and 230 women missing.
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effect estimates. Menwith a positive or a strong positive TST infil-
trate had a 26% (HR = 1.26, 95% CI 1.02–1.55) and 29% (HR = 1.29,
95% CI 1.04–1.61) increased risk of hip fracture, respectively,
compared with those with a negative reaction, whereas there
was no significant difference in risk for women (HR = 0.92, 95%
CI 0.81–1.05 and HR = 0.92, 0.80–1.06, respectively).
Table 2. Hazard Ratios for Hip Fracture by Categories of Tuberculin Skin Test Resulta
Men Women
n (%) Fractures (%) HR 95% CI n (%) Fractures (%) HR 95% CI
Tuberculin skin test (TST)
<4 mm (negative, ref.) 15,869 (13.3) 148 (10.3) 1.00 (ref.) 24,533 (19.7) 413 (19.9) 1.00 (ref.)
4–7 mm (positive) 60,471 (50.6) 708 (49.3) 1.20 1.01–1.44 62,155 (49.9) 987 (47.5) 0.89 0.79–1.00
≥8 mm (strongly positive) 43,268 (36.2) 580 (40.4) 1.24 1.03–1.49 37,996 (30.5) 676 (32.6) 0.90 0.79–1.02
HR per 1 mm increase in
infiltrate size
1.01 0.99–1.03 0.99 0.98–1.01
aEstimated using a Cox regression model including the following covariates: age at TST (years), time between BCG vaccination and TST (years), time
between TST and start of follow-up (years), BMI (categorical), and county (categorical).
Fig 3. Adjusted totalhipbonemineral densitybycategoriesof tuberculin skin test (TST) result amonga subsampleofmen (left,n= 272) andwomen (right,n= 577).
Median with interquartile range (IQR; box) and1.5 x IQR (whiskers). Estimated using a linear regressionmodel including the following covariates: age TST (years),
time from BCG vaccination to TST (years), time from TST to bonemineral density measurement (years), body mass index (categorical), and county (categorical).
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Changing the definition of a strong positive response from
≥8 mm to ≥10 mmproduced similar risk estimates as in themain
model (born 1940 to 1960, BCG at 12 years or older), with a 21%
(HR = 1.21, 95% CI 1.02–1.44) and 25% (HR = 1.25, 95% CI
1.01–1.55) increased risk of hip fracture among men with a pos-
itive or strong positive reaction, respectively, compared with a
negative reaction. There was, however, a slight change among
women, with a statistically significant 11% reduced risk among
the positive group (HR = 0.89, 95% CI 0.79–0.99). The difference
between women with a strong positive reaction versus negative
remained non-significant (HR = 0.95, 95% CI 0.81–1.11).
TST as a continuous measure (millimeters) was not signifi-
cantly associated with risk of hip fracture in any of the sensitivity
analyses.
Bone mineral density
In the subsample with available DXA measurements of total hip
BMD (272 men and 577 women), mean age at the time of DXA
measurement was 52.3 years (range 45 to 62, SD 5.1). In men,
total hip BMD was lowest among those with a strong positive
TST reaction, although no differences between any groups were
statistically significant. There was no clear trend among women.
Data are presented in Fig. 3 and Supplemental Table S1.
Discussion
Our results showed that men with a positive TST after BCG vacci-
nation at a young age had a slightly increased risk of hip fracture
later in life, potentially mediated through increased immune-
mediated bone loss. This notion was also supported by a non-
significantly lower total hip BMD several decades after the
screening among TST positive men, although this analysis had
insufficient statistical power to make clear inferences.
The association between TST measurement and risk of hip frac-
ture was not present among women. A similar sex-specific differ-
ence has previously been described for C-reactive protein (CRP)
and BMD,(29) and there are also indications that men and women
have differing immune responses toward tuberculin/tuberculo-
sis.(30) The impact of female reproductivehealthon immuneactivity
may alsobe important to consider. Immuneactivity differs depend-
ing on the menstrual cycle,(31) and pregnancy has been shown to
reduceTh17activity.(32) A change in thepresenceof sex steroidhor-
mones will also significantly affect adaptive immune responses,(33)
for example after menopause. Most of the women included in the
study population would likely have undergonemenopause during
follow-up. Since there aremultiple factors throughout life that both
impact immune activity and are exclusive to women, it could be
that a single measure of immune activity obtained during young
adulthood is not representative of individual variation in the same
way among women as in men. There are also fewer inherent risk
factors for hip fracture among younger men than among women.
Although the loss of hormones aftermenopausecomprises amajor
risk factor amongwomenandmayoverride smaller influences such
as immune-mediated factors, there is no single comparable factor
among men.
By focusing on younger adults, we aimed to reduce the
impact of differences in environmental exposure on TST and also
to ensure that BCG vaccination had happened under similar cir-
cumstances across the study population. The majority (around
76%) were vaccinated as part of the strictly standardized national
school vaccination program. There was also less variation in lag-
time between vaccination and the TST among the younger
participants, and both age at vaccination and time since vaccina-
tion have been shown to be important factors for the TST reac-
tion after BCG vaccination.(27,28) Results from the sensitivity
analyses, which revealed that both a narrower range of birth year
(1945 to 1960) as well as age at vaccination (12 to 14 years) pro-
duced stronger effect estimates, even though statistical power
was reduced, further support the importance of a young popula-
tion with standardized exposure.
It is hard to reach any definitive conclusion as to what the TST
response specifically represents, as there are multiple immuno-
logical mechanisms involved. However, this complexity is also
an advantage in that it reflects a complete immune response
as it happens in vivo, rather than a single inflammatory marker.
The conventional interpretation of a negative TST after BCG vac-
cination is that the individual did not induce an adequate cell-
mediated immune reaction post vaccination, and thereby lack
memory CD4+ T cells to respond to the tuberculin. The reaction
is generally considered to be Th1-mediated, but Th17 has also
been shown to be an important promoter of both the post-
vaccine response,(14,15) as well as the delayed-type hypersensitiv-
ity reaction measured during TST.(16) A possible involvement of
Th17 activity is in line with our observation of a reduced fracture
risk among the negative group, as Th17 is one of the few CD4+ T
cells with a cytokine profile that is net stimulatory on osteoclas-
togenesis.(4) This would also fit with previous reports of positive
associations between levels of the inflammatory cytokines IL-6/
TNF and fracture risk.(34–37) Still, the specific immunologic mech-
anisms involved in the TST could not be determined in the cur-
rent study and must be investigated using other study designs.
There is also an inherent variability in the tuberculin skin test
that adds uncertainty to our measurements. Although most par-
ticipants were exposed to the same form of BCG vaccine and
testing procedure, there is still an intra-individual variation in
the TST results with the same individual producing slightly differ-
ent induration sizes when tested multiple times.(38) The possibil-
ity also remains that some of the positive test results may have
been caused by exposure to environmental mycobacteriae or
tubercle bacilli.(22)
Another question is whether the immunological tendencies
we have measured are persistent over time, as we followed the
participants up to 59 years. Recent studies of human immune
system variation using post-vaccination responses found little
intra-individual variation over time,(39,40) and even temporal sta-
bility for immunological markers that vary significantly between
individuals.(41) This could imply that the human immune pheno-
type remains stable for large parts of our life, although it is impor-
tant to note that the data points from these studies are separated
by months or years and not decades as in our study.
Several health and lifestyle-related variables occurring
through the life span could influence the association between
immune response and subsequent fracture risk. We have
adjusted for BMI at screening, age, and county. Smoking is well
known to affect both the innate and adaptive immune
system,(42) but given the young age of our participants at the
time of TST measurements, this impact would likely have been
limited. It is also unlikely that the presence of autoimmune disor-
ders should have significantly altered the described risk esti-
mates, given the low prevalence of these conditions during
early life. Individuals with autoimmune disorders are, however,
also more likely to take medication with a detrimental effects
on bone integrity, such as corticosteroids.
We did not have access to information on hip fractures that
could have occurred between the time of measurement of TST
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and the start of follow-up in 1994. It is unlikely that this com-
prised a substantial proportion of all hip fractures, since our pop-
ulation was relatively young. Only an estimated 6.8% of all hip
fractures among men, and 1.7% among women, occur before
55 years of age.(43) Median age at start of follow-up in 1994
was 46 years. The oldest individual in the cohort was 54 years
old at the start of follow-up and 74 years old at the end of
follow-up. The median age at hip fracture was therefore low at
60/62 years (men/women). This compares to a mean age at hip
fracture of 79/82 years (men/women) for the Norwegian popula-
tion as a whole,(44) which means that there likely was a different
profile of risk factors present among our cohort compared with
that in the background population. This was an advantage of
our study design, as prevalent risk factors among older persons
could override any immune-mediated effect. However, this rela-
tively young age of the study population could also imply that
there are several high-energy level fractures present, which we
could not account for. On the other hand, it can also be argued
that such high-energy fractures should be included as outcomes
in observational studies on osteoporosis, as BMD has been
shown to be similarly inversely associated with both high-trauma
and low-trauma nonspine fractures in at least the elderly.(45)
In summary, data from our nationwide cohort showed a con-
sistent trend of increased risk of hip fracture later in life in men
with an increased post-vaccination immune response. This may
be due to an increased immune-mediated bone loss, but there
are several uncertainties as towhich immunological mechanisms
the measured immune response actually represents. This
hypothesis of immune-mediated bone loss was supported by a
non-significant inverse relationship between the immune
response and total hip BMD among a subsample of the study
population, although this analysis was severely underpowered.
There was no similar trend among women. We have speculated
that there are factors unique to women that we could not
account for, which may have affected any potential association.
An increased post-vaccination immune response is associated
with an increased risk of hip fracture decades later among men,
possibly due to increased immune-mediated bone loss. A similar
association was not found among women.
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